Egalet Corp (EGLT) Receives $5.38 Average Price Target from Analysts

Lloyd Doyle
March 15, 2018

Average True Range (14) for Egalet Corporation (EGLT) is stands at 0.07.

Market capitalization is the total market value of all of a company's outstanding shares. For the current quarter Egalet Corporation (NASDAQ:EGLT) has high EPS estimates of $-0.36 in contradiction of low EPS estimates of $-0.4. Morgan Stanley reported 6,616 shares.

Egalet Corporation (EGLT) stock is Overbought or Oversold? Rock Springs Capital Mgmt L P invested in 0.02% or 300,000 shares. Nj State Employees Deferred Compensation Plan stated it has 340,000 shares.

Jvl Advisors L.L.C. holds 9.36% of its portfolio in Evolution Petroleum Corporation for 3.85 million shares. Sta Wealth Management Llc, a Texas-based fund reported 207,895 shares.

Egalet Corporation (NASDAQ:EGLT) received a Buy rating from 1 analysts. Therefore 60% are positive.

The RSI most typically used on a 14-day timeframe, measured on a scale from 0-100, with high and low levels marked at between 70 and 30, respectively. Egalet Ltd had 14 analyst reports since November 4, 2015 according to SRatingsIntel. Genworth Financial, Inc. (GNW) has the market capitalization of 1.53 Billion.

Currently Egalet Corporation (NASDAQ:EGLT)'s shares owned by insiders are 0.1%, whereas shares owned by institutional owners are 61.1%. The firm has "Buy" rating given on Monday, March 12 by Cantor Fitzgerald.

Analyst mean recommendation rating on a stock by the analyst community is at 2.50. The company was maintained on Monday, August 14 by Guggenheim. Stifel Nicolaus downgraded Egalet from a "buy" rating to a "hold" rating and set a $1.50 target price for the a research report on Wednesday, January 3rd. Over the past five trading sessions it is 12.21%; 23.17% for the month; 35.6% for the last quarter; 40.58% for the past six-months; and 58.3% for the last 12 months. About 406,549 shares traded. It has underperformed by 63.37% the S&P500.

Egalet Corporation (EGLT)'s RSI (Relative strength index) is at 57.23, its ATR (Average True Range) value is 0.07, while its Beta factor was calculated at 0.55.

For the year, the company reported that its loss narrowed to $69.4 million, or $2.05 per share. The company had revenue of $7.80 million for the quarter, compared to analyst estimates of $8.54 million. sell-side analysts anticipate that Egalet will post -2.81 earnings per share for the current fiscal year. It has a market cap of $39.31 Million. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product created to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It now has negative earnings. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Goldman Sachs Group Inc. grew its holdings in shares of Egalet Corp (NASDAQ:EGLT) by 515.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article